首页> 外文期刊>Circulation: An Official Journal of the American Heart Association >Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS).
【24h】

Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS).

机译:患者健康状况和心力衰竭成本:ePlerenone后急性心肌梗死心力衰竭疗效和生存研究(以弗所)的见解。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Although a variety of prognostic tools have been shown to predict rehospitalization and mortality in heart failure patients, their utility in assessing future costs is less clear. We assessed whether health status assessment with the Kansas City Cardiomyopathy Questionnaire (KCCQ) predicts future costs in stable heart failure outpatients with left ventricular dysfunction after myocardial infarction. METHODS AND RESULTS: We evaluated 12-month cost utilization data from 1516 heart failure outpatients enrolled in the Quality-of-Life Substudy of the Eplerenone Post-Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Multivariable hierarchical models assessed whether the KCCQ (categorized as 0 to <25, 25 to <50, 50 to <75, and 75 to 100) was an independent predictor of future resource use. At baseline, 685 patients (45.2%) had good health status (KCCQ scores > or =75), whereas 510 (33.6%), 262 (17.3%), and 59 (3.9%) had fair (KCCQ, 50 to 74), poor (KCCQ, 25 to 49), and theworst (KCCQ <25) health status, respectively. After multivariable adjustment, compared with patients with good health status, patients with fair health status incurred incremental 1-year costs of Dollars 1520 (cost ratio, 1.23; 95% confidence interval, 1.05 to 1.43), whereas patients with poor and the worst health status incurred incremental 1-year costs of Dollars 4265 (cost ratio, 1.63; 95% confidence interval, 1.34 to 1.99) and Dollars 8999 (cost ratio, 2.34; 95% confidence interval, 1.62 to 3.38), respectively (P<0.0001 for association with KCCQ). Further adjustment for New York Heart Association class led to only partial attenuation of this relationship (P=0.0002). CONCLUSIONS: Health status assessment predicts resource use and costs over the next year in stable heart failure outpatients with left ventricular dysfunction after myocardial infarction.
机译:背景:虽然已显示各种预后工具可预测心力衰竭患者的再生生殖和死亡率,但它们在评估未来成本方面的效用不太清楚。我们评估了与堪萨斯城心肌病问卷(KCCQ)的健康状况评估是否预测心肌梗死后左心室功能障碍的稳定心力衰竭门诊患者未来成本。方法和结果:我们评估了1516名心力衰竭门诊患者的12个月成本利用数据,纳入ePlerenone后心肌梗死心力衰竭疗效和生存研究(以弗所)。多变量分层模型评估KCCQ(分类为0到<25,25到<50,50至<75,以及75到100)是未来资源使用的独立预测因素。在基线时,685名患者(45.2%)具有良好的健康状况(KCCQ分数>或= 75),而510(33.6%),262名(17.3%)和59(3.9%)公平(Kccq,50至74) ,穷人(kccq,25至49),以及铁路(Kccq <25)的健康状况。经过多变量调整后,与健康状况良好的患者相比,公平健康状况的患者发生了1年的1年费用1520(成本比率,1.23; 95%置信区间,1.05至1.43),而贫困患者和最严重的健康患者现状产生的1年减少1年费用4265(成本比率,1.63; 95%置信区间,1.34至1.99)和美元8999(成本比率,2.34; 95%置信区间,1.62至3.38)(P <0.0001)与kccq相关联。对纽约心脏关联类的进一步调整仅导致这种关系的部分衰减(P = 0.0002)。结论:健康状况评估预测明年在心肌梗死后左心室功能障碍的稳定心力衰竭门诊患者在明年的资源使用和成本。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号